

## Synthesis of enantiomerically pure $\alpha$ -amino acids via chemo- and diastereoselective alkylation of (5*S*)-5-phenyl-5,6-dihydro-2*H*-1,4-oxazin-2-one

Laurence M. Harwood,<sup>a,\*</sup> Simon N. G. Tyler,<sup>a</sup> A. Susan Anslow,<sup>b</sup> Iain D. MacGilp<sup>c</sup> and Michael G. B. Drew<sup>a</sup>


<sup>a</sup> Department of Chemistry, University of Reading, Whiteknights, Reading, RG6 6AD, UK

<sup>b</sup> Glaxo Wellcome Research and Development, Park Road, Ware, SG12 0DP, UK

<sup>c</sup> Glaxo Wellcome Research and Development, Temple Hill, Dartford, DA1 5AH, UK

**Abstract:** (5*S*)-5-Phenyl-5,6-dihydro-2*H*-1,4-oxazin-2-one **2** undergoes Lewis acid-mediated chemo- and diastereoselective nucleophilic addition of Grignard reagents to furnish adducts **3** which can be dismantled to allow ready access to enantiomerically pure (*S*)- $\alpha$ -amino acids **4**. © 1997 Elsevier Science Ltd. All rights reserved.

Synthesis of enantiomerically pure  $\alpha$ -amino acids, particularly unnatural analogues,<sup>1</sup> continues to challenge the organic chemist. A plethora of approaches towards these compounds has been established, of which the use of chiral glycine equivalents has proved extremely profitable.<sup>2a-e</sup> Williams has used chiral oxazin-2-one templates possessing two stereogenic centres to achieve asymmetric induction by diastereocontrolled alkylation via  $\alpha$ -brominated intermediates<sup>2b,c</sup> and there is a healthy literature precedent for the concept of alkylation of acyclic imines to prepare optically active amines.<sup>3a-i</sup> Undeterred by the moderate levels of stereoselectivity often observed with the latter systems,<sup>3a,c,f,i</sup> we decided to investigate the level of stereocontrol available using the isolable cyclic imine (5*S*)-5-phenyl-5,6-dihydro-2*H*-1,4-oxazin-2-one **2**, which we have already employed as a heterodienophile.<sup>4</sup> Diastereoselective alkylation of **2** and subsequent template cleavage through our established protocol<sup>5</sup> would then provide access to enantiomerically pure  $\alpha$ -amino acids **4** (Scheme 1).



**Reagents and conditions:** (i) NBS, propylene oxide, DCM, r.t., 4h; (ii)  $\text{BF}_3 \cdot \text{OEt}_2$  (1.1 eq.), THF,  $-40^\circ\text{C}$ , 2h; (iii)  $\text{RMgX}$  (1.3 eq.), THF,  $-30^\circ\text{C}$ , 30 min; (iv) aq.  $\text{NaHCO}_3$ ; (v)  $\text{H}_2$  (5 bar), 20%  $\text{Pd}(\text{OH})_2/\text{C}$ , TFA, aq. MeOH, 24h; (vi) ion-exchange chromatography.

Scheme 1.

We have reported the application of such an approach to the formation of  $\alpha$ -substituted alanine derivatives, in which the cyclic imine was prepared by cyclisation of (2*S*)-2-phenylglycinol with  $\alpha$ -keto ester derivatives, and alkylated with Grignard reagents using a Lewis acid to facilitate chemoselection between the imine and lactone functionalities.<sup>6</sup> This chemoselectivity is complementary to that observed by Molinski in the absence of a Lewis acid, when phenylmagnesium bromide attacks the ester function of (5*S*)-5-isopropyl-5,6-dihydro-2*H*-1,4-oxazin-2-one with subsequent intramolecular addition of the liberated alkoxide to the imine.<sup>7</sup> The parent system **2**, lacking 3-substitution, cannot be prepared by the direct approach and is known to be readily isomerised to 5-phenyl-3,6-dihydro-

\* Corresponding author. Email: l.m.harwood@reading.ac.uk




Figure 1.

Table 1.

Entry	R	Product	Isolated yield (%)	
			3	4
1	Me	a	34	91
2	Et	b	57	94
3	Bn	c	46	84
4	<i>i</i> -Bu	d	46	98
5	<i>i</i> -Pr	e	43	78
6	<i>t</i> -Bu	f	33	95

2*H*-1,4-oxazin-2-one with concomitant loss of chirality. It was therefore open to question whether the chemoselective alkylation procedure could be applied to this substrate.

Imine **2** was prepared via a one-pot bromination–dehydrobromination of tetrahydrooxazin-2-one **1** with NBS in the presence of propylene oxide,<sup>4</sup> providing **2** of sufficient purity to be used directly. Optimal conditions for the alkylation procedure used low temperature pre-complexation with the Lewis acid at  $-40^{\circ}\text{C}$ , followed by slow addition of the Grignard reagent at  $-30^{\circ}\text{C}$  (Scheme 1).<sup>8</sup>

Scrutiny of the crude product mixtures indicated a single 3,5-*anti*-disubstituted oxazin-2-one **3** to be present. Our stereochemical rationale,<sup>5</sup> invoking nucleophilic attack on the imine carbon in a *quasi*-axial approach to a flattened chair which is conformationally locked by the 5-phenyl substituent yielding the 3,5-*anti*-oxazin-2-one, once again holds good and was supported by X-ray analysis of **3b** and **3c** which were shown to be single enantiomers (Figure 1).<sup>9,14–16</sup>

It should be noted that there is clearly a delicate balance of the conformational energies in this 3,5-*anti*-oxazin-2-one system. There are two conformations adopted by **3b** in the asymmetric unit, the former being a flattened chair thereby giving the 3-ethyl group a *pseudo*-axial position, the latter being a boat conformation, allowing both the 3-ethyl and 5-phenyl groups *pseudo*-equatorial positions. However, the greater steric demand of the 3-benzyl group forces **3c** to adopt solely the boat conformation.

Yields of purified adducts **3** over the two steps are consistent and acceptable for addition of primary and secondary Grignard reagents (Table 1, entries 2–5); although using more hindered reagents resulted in a decrease in overall yield (Table 1, entry 6). This two step process permits expedient chemo- and diastereoselective nucleophilic addition to the imine **2** to furnish oxazin-2-ones **3a–f**,<sup>10,17</sup> in an approach which is diastereocomplementary to hydrogenation of dihydro-2*H*-1,4-oxazin-2-ones to furnish 3,5-*syn*-adducts.<sup>5,11</sup> Degradation of the template by the one-pot hydrogenolysis–hydrolysis procedure<sup>12</sup> afforded the amino acids **4a–f** as colourless powders in high yield after ion-exchange chromatography (Scheme 1, Table 1).<sup>13,18,19</sup>

Since either antipode of **1** can be obtained with equal facility,<sup>11</sup> this protocol allows the synthesis of  $\alpha$ -amino acids in both enantiomeric series. Extension of this methodology towards the construction of specific targets will be reported in due course.

### Acknowledgements

We thank Glaxo Wellcome for a fully-funded research studentship (to S.N.G.T.) and the EPSRC and the University of Reading for funding of the MARresearch Image Plate System.

### References

1. *Chemistry and Biochemistry of the Amino Acids*, Ed. G. C. Barrett, Chapman and Hall, London, 1985; E. A. Bell and R. J. Nash, *Biochemistry of Non-Protein Amino Acids*, Chapman and Hall, London, 1997.
2. (a) P. D. Bailey, J. Clayson and A. N. Boa, *Contemp. Org. Synth.*, **1995**, 2, 173; (b) R. M. Williams in *Advances in Asymmetric Synthesis*, Ed. A. Hassner, JAI Press, London, 1995, Vol. 1, pp. 45–94; (c) R. M. Williams, *Aldrichimica Acta*, **1992**, 25, 11; (d) R. M. Williams and J. A. Hendrix, *Chem. Rev.*, **1992**, 92, 889; (e) R. M. Williams, *Synthesis of Optically Active  $\alpha$ -Amino Acids*, Pergamon Press, Oxford, 1989.
3. For examples, see: (a) J. A. Marco, M. Cardia, J. Murga, F. González and E. Falomir, *Tetrahedron Lett.*, **1997**, 38, 1841; (b) T.-P. Loh, D. S.-C. Ho, K.-C. Xu and K.-Y. Sim, *ibid.*, **1997**, 38, 865; (c) D.-K. Wang, L.-X. Dai, X.-L. Hou and Y. Zhang, *ibid.*, **1996**, 37, 4187; (d) C. Cativiela, M. D. Diaz-de-Villegas and J. A. Gálvez, *Tetrahedron: Asymmetry*, **1996**, 7, 529; (e) L. Chen, R. V. Trilles and J. W. Tilley, *Tetrahedron Lett.*, **1995**, 36, 8715; (f) C. Bellucci, P. G. Cozzi and A. Umani-Ronchi, *ibid.*, **1995**, 36, 7289; (g) T. Basile, A. Bocoum, D. Savoia and A. Umani-Ronchi, *J. Org. Chem.*, **1994**, 59, 7766; (h) A. Bocoum, D. Savoia and A. Umani-Ronchi, *J. Chem. Soc., Chem. Commun.*, **1993**, 1542; (i) A. Bocoum, C. Boga, D. Savoia and A. Umani-Ronchi, *Tetrahedron Lett.*, **1991**, 32, 1367.
4. D. Ager, N. Cooper, G. G. Cox, F. Garro-Hélión and L. M. Harwood, *Tetrahedron: Asymmetry*, **1996**, 7, 2563.
5. G. G. Cox and L. M. Harwood, *Tetrahedron: Asymmetry*, **1994**, 5, 1669.
6. L. M. Harwood, K. J. Vines and M. G. B. Drew, *Synlett*, **1996**, 1051.
7. C. M. Shafer and T. F. Molinski, *J. Org. Chem.*, **1996**, 61, 2044.
8. General two-step procedure for synthesis of adducts **3**: (5*S*)-5-phenyl-3,4,5,6-tetrahydro-2*H*-1,4-oxazin-2-one **1** (0.71 mmol) was prepared as described previously<sup>4</sup> and the crude product immediately dissolved in anhydrous tetrahydrofuran (6 mL) under nitrogen and the solution cooled to  $-40^{\circ}\text{C}$ . Boron trifluoride etherate (0.10 mL, 0.79 mmol, 1.1 eq.) was added in a single portion and the reaction mixture stirred at  $-40^{\circ}\text{C}$  for 2 h, whereupon the requisite Grignard reagent (0.90 mmol, 1.3 eq.) was added dropwise over 15 min. The reaction mixture was stirred for a further 15 min, while the temperature was allowed to rise to  $-30^{\circ}\text{C}$ , and then quenched by the addition of sat. aq.  $\text{NaHCO}_3$  solution. The organic phase was removed, brine added (15 mL) and the aqueous phase further extracted with diethyl ether (2 $\times$ 20 mL). The combined organic fractions were washed with brine, dried over  $\text{MgSO}_4$  and evaporated *in vacuo*. Purification of the residue by flash column chromatography, eluting with diethyl ether:light petroleum (2:5), followed by recrystallisation from diethyl ether–light petroleum furnished adducts **3** as colourless crystalline solids.
9. Crystal data for **3b**:  $\text{C}_{12}\text{H}_{15}\text{NO}_2$ ,  $M=205.26$ , monoclinic, space group  $P2_1$ ,  $a=12.949$  (12),  $b=6.109$  (8),  $c=14.558$  (14) Å,  $\beta=98.224$  (10) $^{\circ}$ ,  $U=1140$  Å<sup>3</sup>,  $Z=4$ ,  $D_c=1.196$  gcm<sup>-3</sup>,  $F(000)=440$ . 3685 Reflections, 3643 independent ( $R_{\text{int}}=0.0307$ ), were collected with  $\text{MoK}\alpha$  radiation using the MARresearch Image Plate System. Final residuals above background were  $R1=0.0557$  and  $wR2=0.1446$ . Crystal data for **3c**:  $\text{C}_{17}\text{H}_{17}\text{NO}_2$ ,  $M=267.33$ , orthorhombic, space group  $P2_12_12_1$ ,  $a=6.518$  (8),  $b=8.476$  (8),  $c=27.21$  (2) Å,  $U=1503$  Å<sup>3</sup>,  $Z=4$ ,  $D_c=1.177$  gcm<sup>-3</sup>,  $F(000)=564$ . 3948 reflections, 2429 independent ( $R_{\text{int}}=0.0344$ ), were collected with  $\text{MoK}\alpha$  radiation using the MARresearch Image Plate System. Final residuals above background were  $R1=0.0555$  and  $wR2=0.1622$ . In each case the crystals were positioned at 70 mm from the Image Plate and 95 frames were measured at  $2^{\circ}$  intervals with a counting time of 2 min. Data analysis was carried out

with the XDS program.<sup>14</sup> The structures were determined by direct methods using SHELX86.<sup>15</sup> Non-hydrogen atoms were refined with anisotropic thermal parameters; hydrogen atoms bonded to carbon were included in geometric positions with isotropic thermal parameters and the hydrogen atom bonded to nitrogen was located in a difference Fourier map and refined independently. The structures were then refined by full-matrix least-squares on  $F^2$  using SHELXL.<sup>16</sup>

10. Adducts **3a–f** gave spectroscopic data, microanalytical and/or high resolution mass spectrometric data in accordance with their assigned structures. Typical data: **3c**: mp 108–111°C; Found C: 76.2, H: 6.43, N: 5.23%,  $C_{17}H_{17}NO_2$  requires C: 76.4, H: 6.41, N: 5.24%;  $\nu_{\max}$  (KBr) 3347, 2912, 1734, 1491, 1450, 1204, 1164, 1134, 1042, 757 and 701  $cm^{-1}$ ;  $\delta_H$  (250 MHz,  $CDCl_3$ ) 7.46–7.17 (10H, m), 4.45–4.26 (3H, m), 4.09 (1H, dd,  $J$  9.4,  $J'$  4.3 Hz), 3.31 (1H, dd,  $J$  13.9,  $J'$  4.3 Hz), 3.19 (1H, dd,  $J$  13.9,  $J'$  9.5 Hz) and 1.84 (1H, br s);  $\delta_C$  (100.4 MHz,  $CDCl_3$ ) 170.62, 137.97, 136.93, 129.34, 128.92, 128.88, 128.46, 127.11, 126.94, 73.65, 57.23, 52.51 and 37.96;  $m/z$  (CI,  $NH_3$ ) 268 (24%,  $MH^+$ ), 176 (100), 117 (24), 104 (73), 91 (71) and 77 (10);  $[\alpha]_D^{25}$  –70.5 (c 1.27,  $CHCl_3$ ), lit.<sup>17</sup>  $[\alpha]_D^{22}$  –55.8 (c 3.00,  $CHCl_3$ ).
11. J. F. Dellaria, Jr and B. D. Santarsiero, *J. Org. Chem.*, **1989**, *54*, 3916.
12. General procedure for synthesis of  $\alpha$ -amino acids **4**: the requisite oxazin-2-one **3** (100 mg, 0.37 mmol) was dissolved in methanol (5 mL) in a Fischer–Porter bottle containing Pearlman's catalyst (100 mg), trifluoroacetic acid (0.1 mL) and water (0.5 mL). The bottle was pressurised with hydrogen to 5 bar and the mixture stirred rapidly for 24 h. After depressurisation the mixture was filtered through Celite<sup>®</sup> and the solvent evaporated *in vacuo*. The residue was purified by ion-exchange chromatography (Dowex<sup>®</sup> 50WX8-100) and triturated with diethyl ether to furnish  $\alpha$ -amino acids **4** as colourless powders.
13.  $\alpha$ -Amino acids **4a–f** gave spectroscopic data in accordance with their assigned structures. Specific rotations: **4a**:  $[\alpha]_D^{24}$  +2.4 (c 0.29,  $H_2O$ ), lit.<sup>18</sup>  $[\alpha]_D^{25}$  +2.4 (c 10.00,  $H_2O$ ). **4b**:  $[\alpha]_D^{27}$  +7.3 (c 0.30,  $H_2O$ ), lit.<sup>18</sup>  $[\alpha]_D^{19}$  +8.4 (c 4.00,  $H_2O$ ). **4c**:  $[\alpha]_D^{23}$  –32.2 (c 0.32,  $H_2O$ ), lit.<sup>18</sup>  $[\alpha]_D^{20}$  –35.1 (c 1.94,  $H_2O$ ). **4d**:  $[\alpha]_D^{24}$  –9.2 (c 0.36,  $H_2O$ ), lit.<sup>18</sup>  $[\alpha]_D^{25}$  –10.8 (c 2.20,  $H_2O$ ). **4e**:  $[\alpha]_D^{24}$  +10.7 (c 0.30,  $H_2O$ ), lit.<sup>18</sup>  $[\alpha]_D^{20}$  +13.9 (c 0.90,  $H_2O$ ). **4f**:  $[\alpha]_D^{24}$  –6.7 (c 0.30,  $H_2O$ ), lit.<sup>19</sup>  $[\alpha]_D^{20}$  –9.5 (c 3.00,  $H_2O$ ).
14. W. Kabsch, *J. Appl. Cryst.*, **1988**, *21*, 916.
15. G. M. Sheldrick, *Acta Cryst., Sect. A*, **1990**, *46*, 467.
16. G. M. Sheldrick, SHELXL program for crystal structure refinement, University of Göttingen, 1993.
17. A. N. Boa, A. L. Guest, P. R. Jenkins, J. Fawcett, D. R. Russell and D. Waterson, *J. Chem. Soc., Perkin Trans. 1*, **1993**, 477.
18. *The Merck Index*, 12th Edition, Ed. S. Budavari, Merck and Co., Rahway, 1996.
19. *Catalogue Handbook of Fine Chemicals*, Aldrich Chemical Company, Gillingham, 1996–1997.

(Received in UK 5 November 1997)